title: [Clinical stage I seminoma. Is surveillance a new therapy standard?].
abstract: BACKGROUND
  The therapy of stage I seminoma is under constant change. While surveillance, adjuvant radiotherapy and adjuvant chemotherapy were seen as equal therapeutic alternatives up to a few years ago, recently published studies make it necessary to adopt a more differentiated approach.
  
  
  CONCLUSIONS
  In this review, recent data on the long-term effects of adjuvant radiotherapy and chemotherapy, the question of risk stratification as well as the advantages and limitations of a surveillance strategy are discussed.
authors: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Prittwitzstraße 43, 89075, Ulm, Deutschland.
authors: F
authors: F
authors: Zengerling
authors: J
authors: J
authors: Müller
authors: A J
authors: AJ
authors: Schrader
authors: M
authors: M
authors: Schrader
mesh_terms: D017024:Chemotherapy, Adjuvant / Q000379:methods*; D003657:Decision Making; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D018570:Risk Assessment / Q000379:methods; D018239:Seminoma / Q000175:diagnosis* / Q000628:therapy*; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D016896:Treatment Outcome
references: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):242-9
references: 21236595
references: Eur Urol. 2010 Apr;57(4):673-8
references: 19545941
references: J Clin Oncol. 2012 Nov 10;30(32):4004-10
references: 23071246
references: J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65
references: 16174857
references: BJU Int. 2012 Mar;109(5):706-12
references: 21883828
references: Eur Urol. 2002 Dec;42(6):553-62; discussion 562-3
references: 12477650
references: Lancet. 2006 Mar 4;367(9512):754-65
references: 16517276
references: J Clin Oncol. 2009 Sep 10;27(26):4327-32
references: 19652075
references: J Clin Oncol. 2011 Jul 20;29(21):2883-8
references: 21690479
references: Histopathology. 2012 May;60(6B):E12-8
references: 22394436
references: J Clin Oncol. 2011 Feb 20;29(6):719-25
references: 21205748
references: Ann Oncol. 2013 May;24(5):1332-7
references: 23293116
references: Int J Cancer. 2011 Dec 15;129(12):2867-74
references: 21626506
references: Ann Oncol. 2013 Apr;24(4):878-88
references: 23152360
references: J Clin Oncol. 1996 Nov;14(11):2933-9
references: 8918490
references: J Clin Oncol. 2011 Dec 10;29(35):4677-81
references: 22042940
references: Ann Oncol. 2008 Mar;19(3):443-7
references: 18048383
references: Am J Pediatr Hematol Oncol. 1985 Summer;7(2):132-40
references: 3842558
references: J Clin Oncol. 2009 May 1;27(13):2129-36
references: 19289622
references: Cancer Epidemiol. 2013 Aug;37(4):370-3
references: 23683844
references: Eur J Cancer. 1997 Feb;33(2):253-62
references: 9135497
references: Lancet. 2005 Jul 23-29;366(9482):293-300
references: 16039331
references: J Clin Oncol. 2011 Mar 10;29(8):957-62
references: 21282539
references: Eur Urol. 2008 Mar;53(3):478-96
references: 18191324
references: BJU Int. 2013 Jun;111(8):1287-93
references: 23469865
references: J Clin Oncol. 2002 Nov 15;20(22):4448-52
references: 12431967
references: J Urol. 2009 Feb;181(2):627-32; discussion 632-3
references: 19091344